Last month, the FDA approved Bolt Medical's commencement of the global FRACTURE IDE clinical trial of its IVL coronary system. Last November, Boston Scientific signed an agreement to acquire ...
Argus raised the firm’s price target on Boston Scientific (BSX) to $130 from $105 and keeps a Buy rating on the shares. The firm sees strong ...
Argus Research analyst David Toung maintained a Buy rating on Boston Scientific (BSX – Research Report) on February 14. The company’s shares ...
(RTTNews) - Boston Scientific Corp. (BSX) announced on Wednesday its agreement to acquire the remaining 74 ... subjects across several platforms. RTT's Financial Newswire is relied upon by some ...
You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...
So far, BSX stock has risen 19% year-to-date. Separately, CROX reports earnings tomorrow. Will the stock pop on the news? See ...
furthering company's strategy to address coronary and peripheral disease MARLBOROUGH, Mass., Jan. 8, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into ...
Jan. 8, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has entered into a definitive agreement to acquire Bolt ... used to support U.S. Food and Drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results